摘要
神经内分泌瘤(NET)是一种相对少见的异质性肿瘤。近年来由于诊断技术的提升,NET发病率呈显著上升趋势。随着分子影像技术的发展,核素诊疗一体化为传统的先诊断后治疗模式提供了全新思路。对于无法手术切除的NET患者,可以应用放射性核素标记的生长抑素类似物^(177)Lu-DOTATATE,其既可发射γ射线用于显像,又可发射β射线用于肿瘤内照射治疗,将诊断和靶向治疗融于一体,还可实时监测肿瘤治疗效果。文章就NET的核素诊疗一体化应用进展进行介绍。
Neuroendocrine tumor(NET)is a relatively rare and heterogeneous tumor.In recent years,with the improvement of diagnostic techniques,its incidence rate has been increased significantly.Due to the development of molecular imaging,radionuclide theranostics provide a new idea for the traditional mode of diagnosis before treatment.For patients with NET that cannot be surgically excised,radionuclide-labeled somatostatin analogue^(177)Lu-DOTATATE can emit both gamma rays for imaging and beta rays for tumor internal radiation therapy,which integrates diagnosis and targeted therapy,and monitors the therapeutic effect of tumors in real time.This article reviews application progress of radionuclide theranostics in patients with NET.
作者
张紫桑
兰晓莉
张永学
Zhang Zisang;Lan Xiaoli;Zhang Yongxue(Department of Nuclear Medicine,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China;Key Laboratory of Molecular Imaging of Hubei Province,Wuhan 430022,China)
出处
《肿瘤研究与临床》
CAS
2020年第12期813-817,共5页
Cancer Research and Clinic
